Regulatory Replimune rebounds to win FDA approval of melanoma drug BioPharma DiveThe accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.OncologyRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) BioPharma Dive The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists. Oncology Read full story Post navigation Previous: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu VaccineNext: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026